These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 30553134)

  • 1. Delivery of miR-212 by chimeric peptide-condensed supramolecular nanoparticles enhances the sensitivity of pancreatic ductal adenocarcinoma to doxorubicin.
    Chen W; Zhou Y; Zhi X; Ma T; Liu H; Chen BW; Zheng X; Xie S; Zhao B; Feng X; Dang X; Liang T
    Biomaterials; 2019 Feb; 192():590-600. PubMed ID: 30553134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric peptide supramolecular nanoparticles for plectin-1 targeted miRNA-9 delivery in pancreatic cancer.
    Wu Y; Tang Y; Xie S; Zheng X; Zhang S; Mao J; Wang B; Hou Y; Hu L; Chai K; Chen W
    Theranostics; 2020; 10(3):1151-1165. PubMed ID: 31938057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma.
    Mikamori M; Yamada D; Eguchi H; Hasegawa S; Kishimoto T; Tomimaru Y; Asaoka T; Noda T; Wada H; Kawamoto K; Gotoh K; Takeda Y; Tanemura M; Mori M; Doki Y
    Sci Rep; 2017 Feb; 7():42339. PubMed ID: 28198398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA-323-3p inhibits cell invasion and metastasis in pancreatic ductal adenocarcinoma via direct suppression of SMAD2 and SMAD3.
    Wang C; Liu P; Wu H; Cui P; Li Y; Liu Y; Liu Z; Gou S
    Oncotarget; 2016 Mar; 7(12):14912-24. PubMed ID: 26908446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miRNA-1290 Promotes Aggressiveness in Pancreatic Ductal Adenocarcinoma by Targeting IKK1.
    Ta N; Huang X; Zheng K; Zhang Y; Gao Y; Deng L; Zhang B; Jiang H; Zheng J
    Cell Physiol Biochem; 2018; 51(2):711-728. PubMed ID: 30463064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The miR-217 microRNA functions as a potential tumor suppressor in pancreatic ductal adenocarcinoma by targeting KRAS.
    Zhao WG; Yu SN; Lu ZH; Ma YH; Gu YM; Chen J
    Carcinogenesis; 2010 Oct; 31(10):1726-33. PubMed ID: 20675343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macrophage-derived exosomal microRNA-501-3p promotes progression of pancreatic ductal adenocarcinoma through the TGFBR3-mediated TGF-β signaling pathway.
    Yin Z; Ma T; Huang B; Lin L; Zhou Y; Yan J; Zou Y; Chen S
    J Exp Clin Cancer Res; 2019 Jul; 38(1):310. PubMed ID: 31307515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MiR-143-3p suppresses tumorigenesis in pancreatic ductal adenocarcinoma by targeting KRAS.
    Xie F; Li C; Zhang X; Peng W; Wen T
    Biomed Pharmacother; 2019 Nov; 119():109424. PubMed ID: 31521891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MiR-361-3p regulates ERK1/2-induced EMT via DUSP2 mRNA degradation in pancreatic ductal adenocarcinoma.
    Hu J; Li L; Chen H; Zhang G; Liu H; Kong R; Chen H; Wang Y; Li Y; Tian F; Lv X; Li G; Sun B
    Cell Death Dis; 2018 Jul; 9(8):807. PubMed ID: 30042387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upregulation of miR-194 contributes to tumor growth and progression in pancreatic ductal adenocarcinoma.
    Zhang J; Zhao CY; Zhang SH; Yu DH; Chen Y; Liu QH; Shi M; Ni CR; Zhu MH
    Oncol Rep; 2014 Mar; 31(3):1157-64. PubMed ID: 24398877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Context-dependent function of the deubiquitinating enzyme USP9X in pancreatic ductal adenocarcinoma.
    Cox JL; Wilder PJ; Wuebben EL; Ouellette MM; Hollingsworth MA; Rizzino A
    Cancer Biol Ther; 2014 Aug; 15(8):1042-52. PubMed ID: 24841553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plectin-1-targeted recognition for enhancing comprehensive therapy in pancreatic ductal adenocarcinoma.
    Zhu Q; Zeng S; Yang J; Zhuo J; Wang P; Wen S; Fang C
    Nanoscale; 2024 Oct; 16(39):18584-18596. PubMed ID: 39291372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SOX2 functions as a molecular rheostat to control the growth, tumorigenicity and drug responses of pancreatic ductal adenocarcinoma cells.
    Wuebben EL; Wilder PJ; Cox JL; Grunkemeyer JA; Caffrey T; Hollingsworth MA; Rizzino A
    Oncotarget; 2016 Jun; 7(23):34890-906. PubMed ID: 27145457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated miR-483-3p expression is an early event and indicates poor prognosis in pancreatic ductal adenocarcinoma.
    Wang C; Sun Y; Wu H; Yu S; Zhang L; Meng Y; Liu M; Yang H; Liu P; Mao X; Lu Z; Chen J
    Tumour Biol; 2015 Dec; 36(12):9447-56. PubMed ID: 26124009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancer of zeste homolog 2 silences microRNA-218 in human pancreatic ductal adenocarcinoma cells by inducing formation of heterochromatin.
    Li CH; To KF; Tong JH; Xiao Z; Xia T; Lai PB; Chow SC; Zhu YX; Chan SL; Marquez VE; Chen Y
    Gastroenterology; 2013 May; 144(5):1086-1097.e9. PubMed ID: 23395645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primate-specific miRNA-637 inhibited tumorigenesis in human pancreatic ductal adenocarcinoma cells by suppressing Akt1 expression.
    Xu RL; He W; Tang J; Guo W; Zhuang P; Wang CQ; Fu WM; Zhang JF
    Exp Cell Res; 2018 Feb; 363(2):310-314. PubMed ID: 29366808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Global microRNA expression profiling of microdissected tissues identifies miR-135b as a novel biomarker for pancreatic ductal adenocarcinoma.
    Munding JB; Adai AT; Maghnouj A; Urbanik A; Zöllner H; Liffers ST; Chromik AM; Uhl W; Szafranska-Schwarzbach AE; Tannapfel A; Hahn SA
    Int J Cancer; 2012 Jul; 131(2):E86-95. PubMed ID: 21953293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upregulated circular RNA circ_0030235 predicts unfavorable prognosis in pancreatic ductal adenocarcinoma and facilitates cell progression by sponging miR-1253 and miR-1294.
    Xu Y; Yao Y; Gao P; Cui Y
    Biochem Biophys Res Commun; 2019 Jan; 509(1):138-142. PubMed ID: 30591218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-21 is induced early in pancreatic ductal adenocarcinoma precursor lesions.
    du Rieu MC; Torrisani J; Selves J; Al Saati T; Souque A; Dufresne M; Tsongalis GJ; Suriawinata AA; Carrère N; Buscail L; Cordelier P
    Clin Chem; 2010 Apr; 56(4):603-12. PubMed ID: 20093556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of CD40 targeting miR-224 and miR-486 on the progression of pancreatic ductal adenocarcinomas.
    Mees ST; Mardin WA; Sielker S; Willscher E; Senninger N; Schleicher C; Colombo-Benkmann M; Haier J
    Ann Surg Oncol; 2009 Aug; 16(8):2339-50. PubMed ID: 19475450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.